{"groups":[{"description":"Taken orally twice daily","id":"FG000","title":"Olaparib 300mg Tablets"},{"description":"Taken orally twice daily","id":"FG001","title":"Placebo Tablets"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Severe non-compliance to protocol"},{"reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"14"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"26"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"260"},{"groupId":"FG001","numSubjects":"131"}],"comment":"(Randomised to study treatment)","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"183"},{"groupId":"FG001","numSubjects":"91"}],"comment":"(Ongoing study at time of PFS analysis DCO:17 May 2018)","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"77"},{"groupId":"FG001","numSubjects":"40"}],"type":"NOT COMPLETED"}],"title":"Overall Study (Global Cohort)"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"6"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"20"}],"comment":"(Randomised to study treatment)","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"14"}],"comment":"(Ongoing study at time of PFS analysis DCO:17 May 2018)","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Overall Study (China Cohort)"}],"preAssignmentDetails":"It was planned that approximately 344 women in the Global Cohort, and 53 women in the China Cohort, with BRCA mutated ovarian cancer patients who are in clinical complete or partial response following first line platinum based chemotherapy were to receive olaparib 300 mg bd or matching placebo in a 2:1 ratio.","recruitmentDetails":"Global Cohort: 391 randomised. First/Last patient randomised 03Sep2013/06Mar2015.\n\nChina Cohort: 64 randomised. First/Last patient randomised 09Jan2015/22Mar2016.\n\nA total of 450 patients randomised (386 global cohort only, 64 China cohort (of which 5 included in global cohort)). Global Cohort used for hypotheses testing of study."}